Completed PHASE2 INTERVENTIONAL 2-arm NCT04930549

Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC) (DAPAVASC)

Impact of Dapagliflozin on Vascular Function in Chronic Kidney Disease Patients

Sponsor: AstraZeneca

Interventions Applanation tonometry Dapagliflozin 10Mg Tab Placebo haemodynamics parameters impedance cardiography post-ischemic hyperemia of forearm

Updated 6 times since 2021 Last updated: Feb 4, 2026 Started: Oct 18, 2022 Primary completion: Sep 23, 2024 Completion: Sep 23, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Renal Insufficiency, Chronic, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE2

Status: Unknown → Completed
Sep 2024 — Feb 2026 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Nov 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Nov 2021 — Nov 2023 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Sep 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
University Hospital, Rouen

Data source: University Hospital, Rouen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bois-Guillaume, France
• Rouen, France